Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai To Establish U.K. Facility To Take Drugs From R&D To Market

This article was originally published in PharmAsia News

Executive Summary

Eisai is opening a facility in the United Kingdom to take drugs from research through marketing, its first production base in Europe. The $165 million site is intended to more than double the company's drug researchers, to 60, and focus on developing drugs to treat mental ailments such as dementia. In a change from outsourcing its work to Europe, Eisai has decided to use a U.K. location to do research and develop, produce drugs and market them. Eisai expects to begin packaging drugs in the current fiscal year and produce pills and powders in fiscal 2010 with a capacity of producing 400 million pills a year. (Click here for more - a subscription may be required

You may also be interested in...



BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

BIO 2021 Notebook: Best Practices For Business Development

The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.

Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis

The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.

UsernamePublicRestriction

Register

SC072038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel